Peer Interventions for Autism
(PIPA Trial)
Trial Summary
What is the purpose of this trial?
This proposal will evaluate a series of peer-mediated interventions (PMIs) for preschool children (3 to 6 years) with ASD and limited or no spoken language, using an innovative Sequential Multiple Assignment Randomized Trial (SMART) design. Available evidence supports the beneficial effects of PMIs for improving social communication in children with ASD. Peer-related social competence is vital to a wide range of child outcomes, such as improved communication and fewer behavioral problems. Unfortunately, approximately 30% of children with ASD remain minimally-verbal in kindergarten, restricting participation in inclusive activities. Recent studies report improved communication after a speech-generating device (SGD) is included in treatment. Effective interventions that can be modified is necessary to ensure optimal communication outcomes when children do not make anticipated progress. A strength of the study is that these interventions can be adopted by community-based, early service providers. All participants will receive an adapted Stay-Play-Talk (SPT) peer-mediated intervention that varies in active ingredients. With SMART designs, it is possible to test and identify alternative combinations of PMI approaches, such as the addition of a SGD. In this study, 132 preschoolers with ASD (and N=264 peers without disabilities) will be initially randomized to SPT and SGD with spoken peer input only (SPT Basic; peers taught to model language) or SPT and SGD with augmented peer input (SPT Plus; peers taught to use verbal language models concurrently with the SGD). Each child's response to treatment after 5 weeks will determine that child's next phase in the SMART design. Children showing a positive response will continue in their originally assigned group; slow responders will be randomly assigned to receive added treatment components to improve communication (either SPT Plus or SPT Advanced). SPT Advanced adds direct instruction strategies (i.e., adult prompts, reinforcers, and teaching trials) to increase child vocalizations in SGD interventions. The use of a SMART design extends our prior work by testing the systematic addition of selected peer-mediated strategies in combination with an SGD that allows for flexible application of interventions based on child response. The investigators have assembled an outstanding team of highly qualified investigators with complementary skills in preschool assessment, language intervention, clinical trials, and statistics.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
Is Peer-Mediated Intervention (PMI) safe for humans?
How is the Stay-Play-Talk treatment different from other autism treatments?
The Stay-Play-Talk treatment is unique because it uses typically developing peers to help children with autism improve their social skills and interactions, focusing on real-life settings like schools and communities. This peer-mediated approach is different from other treatments that may not involve peers as active participants in the therapy process.12345
Research Team
Eligibility Criteria
This trial is for preschoolers aged 3 to 6 with Autism Spectrum Disorder who have limited or no spoken language. They should be using or ready to use a speech-generating device and primarily speak English at home. Children must not have major medical conditions besides ASD, lack symbol discrimination skills, or have impairments that prevent play with peers.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline
Baseline observations and assessments are conducted, including peer recruitment and training, and initial setup of interventions
Treatment
Participants receive the Stay-Play-Talk (SPT) intervention with or without Speech-Generating Device (SGD) for 5 weeks, followed by re-randomization based on response
Adaptive Treatment
Participants continue with their assigned intervention or receive additional treatment components based on response status for 12 weeks
Follow-up
Participants are monitored for communication and behavioral outcomes post-treatment
Treatment Details
Interventions
- Stay-Play-Talk Advanced (Behavioral Intervention)
- Stay-Play-Talk Basic (Behavioral Intervention)
- Stay-Play-Talk Plus (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Kansas
Lead Sponsor
Lynne A. Bui
University of Kansas
Chief Medical Officer since 2017
MD from the David Geffen UCLA School of Medicine, BA in Molecular and Cell Biology from University of California, Berkeley
Randy Milby
University of Kansas
Chief Executive Officer since 2017
BS in Pharmacy from The University of Kansas, MBA in Finance/Marketing from Washington University in St. Louis – Olin Business School
Emory University
Collaborator
Dr. R. Donald Harvey
Emory University
Chief Medical Officer
MD from Emory University School of Medicine
Dr. George Painter
Emory University
Chief Executive Officer since 2013
PhD in Synthetic Organic Chemistry from Emory University
University of North Carolina
Collaborator
Michael O'Rand
University of North Carolina
Chief Executive Officer since 2022
PhD in Biology from Temple University
Dr. Miller
University of North Carolina
Chief Medical Officer since 2024
MD from Albert Einstein College of Medicine